The stock of Pfizer Inc. (PFE) has gone down by -0.88% for the week, with a -7.86% drop in the past month and a -16.03% drop in the past quarter. The volatility ratio for the week is 1.64%, and the volatility levels for the past 30 days are 1.87% for PFE. The simple moving average for the last 20 days is -4.94% for PFE stock, with a simple moving average of -17.67% for the last 200 days.
Is It Worth Investing in Pfizer Inc. (NYSE: PFE) Right Now?
Pfizer Inc. (NYSE: PFE) has a higher price-to-earnings ratio of 8.96x compared to its average ratio. compared to its average ratio and a 36-month beta value of 0.59. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 16 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price point forecasted by analysts for Pfizer Inc. (PFE) is $43.67, which is $10.45 above the current market price. The public float for PFE is 5.64B, and currently, short sellers hold a 0.89% ratio of that float. The average trading volume of PFE on September 19, 2023 was 25.04M shares.
PFE) stock’s latest price update
Pfizer Inc. (NYSE: PFE)’s stock price has plunge by -1.26relation to previous closing price of 34.07. Nevertheless, the company has seen a -0.88% plunge in its stock price over the last five trading sessions. Investopedia reported 2023-09-18 that Moderna (MRNA) was the worst-performing stock in the S&P 500 as shares dropped 9% after Pfizer CFO David Denton said the outlook for vaccine rates this year got a significant “haircut.” Pfizer (PFE) shares also dropped, declining 1%.
Analysts’ Opinion of PFE
Many brokerage firms have already submitted their reports for PFE stocks, with JP Morgan repeating the rating for PFE by listing it as a “Neutral.” The predicted price for PFE in the upcoming period, according to JP Morgan is $41 based on the research report published on July 17, 2023 of the current year 2023.
PFE Trading at -6.01% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.76% of loss for the given period.
Volatility was left at 1.87%, however, over the last 30 days, the volatility rate increased by 1.64%, as shares sank -8.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.32% lower at present.
During the last 5 trading sessions, PFE fell by -0.88%, which changed the moving average for the period of 200-days by -32.03% in comparison to the 20-day moving average, which settled at $35.24. In addition, Pfizer Inc. saw -34.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from Gottlieb Scott, who purchase 1,000 shares at the price of $38.58 back on May 08. After this action, Gottlieb Scott now owns 6,000 shares of Pfizer Inc., valued at $38,580 using the latest closing price.
Gottlieb Scott, the Director of Pfizer Inc., purchase 1,000 shares at $38.42 during a trade that took place back on May 05, which means that Gottlieb Scott is holding 5,000 shares at $38,425 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- +37.43 for the present operating margin
- +61.89 for the gross margin
The net margin for Pfizer Inc. stands at +31.26. The total capital return value is set at 29.59, while invested capital returns managed to touch 25.39. Equity return is now at value 22.10, with 10.60 for asset returns.
Based on Pfizer Inc. (PFE), the company’s capital structure generated 40.82 points at debt to equity in total, while total debt to capital is 28.99. Total debt to assets is 19.80, with long-term debt to equity ratio resting at 37.09. Finally, the long-term debt to capital ratio is 26.34.
When we switch over and look at the enterprise to sales, we see a ratio of 2.68, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 8.95 and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.22.
Conclusion
To put it simply, Pfizer Inc. (PFE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
